VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Male or female on stable dose of IgPro20           │ Male or female on stable dose of IgPro20           │     100 │
│ (Hizentra) therapy                                 │ (Hizentra) therapy                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential must be using and  │ Women of childbearing potential must be using and  │     100 │
│ agree to continue using medically approved         │ agree to continue using medically approved         │         │
│ contraception (which must be discussed with the    │ contraception (which must be discussed with the    │         │
│ study doctor) and must have a negative pregnancy   │ study doctor) and must have a negative pregnancy   │         │
│ test at screening                                  │ test at screening                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with PID, eg, with a diagnosis of common  │ Subjects with PID, eg, with a diagnosis of common  │     100 │
│ variable immunodeficiency or X-linked              │ variable immunodeficiency or X-linked              │         │
│ agammaglobulinemia, as defined by the Pan American │ agammaglobulinemia, as defined by the Pan American │         │
│ Group for Immune Deficiency and the European       │ Group for Immune Deficiency and the European       │         │
│ Society of Immune Deficiencies                     │ Society of Immune Deficiencies                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ With infusion parameters as specified below        │ With infusion parameters as specified below        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Experience with pump-assisted infusions of IgPro20 │ Experience with pump-assisted infusions of IgPro20 │     100 │
│ at the tolerated flow rate of 25 mL/h per          │ at the tolerated flow rate of 25 mL/h per          │         │
│ injection site for at least 1 month prior to Day 1 │ injection site for at least 1 month prior to Day 1 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Experience with pump-assisted infusions of IgPro20 │ Experience with pump-assisted infusions of IgPro20 │     100 │
│ at tolerated volumes of 25 mL/injection site for   │ at tolerated volumes of 25 mL/injection site for   │         │
│ at least 1 month prior to Day 1                    │ at least 1 month prior to Day 1                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Experience with frequent (2-7 times per week)      │ Experience with frequent (2-7 times per week)      │     100 │
│ infusions of IgPro20 at the tolerated flow rate of │ infusions of IgPro20 at the tolerated flow rate of │         │
│ approximately 0.5 mL/min (equivalent of 25-30      │ approximately 0.5 mL/min (equivalent of 25-30      │         │
│ mL/h) per injection site for at least 1 month      │ mL/h) per injection site for at least 1 month      │         │
│ prior to Day 1. The dose (volume) per injection    │ prior to Day 1. The dose (volume) per injection    │         │
│ site should not exceed 25 mL                       │ site should not exceed 25 mL                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing serious bacterial infections at the time   │ Ongoing serious bacterial infections at the time   │     100 │
│ of screening                                       │ of screening                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other significant medical conditions that could    │ Other significant medical conditions that could    │     100 │
│ increase the risk to the subject                   │ increase the risk to the subject                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females who are pregnant, breast feeding, or       │ Females who are pregnant, breast feeding, or       │     100 │
│ planning a pregnancy during the course study       │ planning a pregnancy during the course study       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in a study with an Investigational   │ Participation in a study with an Investigational   │     100 │
│ Medicinal Product (IMP) other than IgPro20 within  │ Medicinal Product (IMP) other than IgPro20 within  │         │
│ three months prior to enrollment                   │ three months prior to enrollment                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g)      │ Total weekly IgPro20 dose of = 50 mL (= 10 g)      │      96 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒══════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                            │ CHIA Criteria                                   │   Score │
╞══════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Pump-Assisted Volume Cohort subjects only    │ Other significant medical conditions that could │      35 │
│                                              │ increase the risk to the subject                │         │
├──────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Pump-Assisted Flow Rate Cohort subjects only │ Other significant medical conditions that could │      37 │
│                                              │ increase the risk to the subject                │         │
├──────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Manual Push Flow Rate Cohort subjects only   │ Other significant medical conditions that could │      39 │
│                                              │ increase the risk to the subject                │         │
├──────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 2 Years             │ Male or female on stable dose of IgPro20        │      40 │
│                                              │ (Hizentra) therapy                              │         │
╘══════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 95
Average Levenshtein Ratio of individual lines: 84.1875
OverAll Ratio: 89.59375
